A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Osso VR Raises $66 Million

Osso VR, a validated virtual reality (VR) surgical training and assessment platform, today announced that it has secured $66 million in Series C funding led by Oak HC/FT. The round also includes participation from Signalfire, GSR Ventures, Tiger Global Management and Kaiser Permanente Ventures.

The capital will be used to accelerate Osso VR’s initiative to broaden access to surgical education for all healthcare professionals and continue the investment in hiring top-tier talent to bring high-fidelity surgical training experiences to additional specialty areas.
Osso VR produces on-demand, immersive modules that allow surgical teams to train independently or collaboratively in a virtual environment before ever stepping foot into a real operating room. Medical device companies also use Osso VR to introduce technology digitally, addressing many challenges of traditional educational pathways ⁠such as conflicting physician schedules, remote staff, and costly travel. With Osso VR, more surgeons can practice utilizing complex medical technologies to more rapidly offer their patients access to the best procedures with optimal outcomes.
“Oak HC/FT is continuously seeking new opportunities to support innovative companies impacting the healthcare industry in a meaningful way,” said Vig Chandramouli, Partner at Oak HC/FT. “Osso VR is well positioned to become the gold standard for all surgical training and continuing education, and we’re thrilled to work alongside this impassioned and committed team.”
Osso VR currently partners with leading global medical device companies, including Johnson & Johnson, Stryker, Zimmer Biomet, and Smith + Nephew. The company’s modules cover multiple specialty areas, such as orthopedics, spine, interventional cardiology, and general surgery, amongst others.
“The future at Osso VR is incredibly bright. Each step of the way, we’ve stayed true to our mission to democratize healthcare and seen the results that our platform brings to surgical training and  assessment,” said Justin Barad, MD, CEO and Co-Founder of Osso VR. “This round of investment supports the next step of our journey to provide access to all healthcare professionals. I couldn’t be more excited to take this next step with such a talented, passionate team.”
The company has more than 150 employees and plans to grow exponentially over the next year. Osso VR designs and develops all virtual experiences in-house and has hired talent across an array of industries, including healthcare, technology, movies and gaming. The company boasts the largest team of medical illustrators in the world.
The funding news comes on the heels of Osso VR winning the prestigious SXSW Innovation Award for VR, AR, and MR. The company is also exhibiting at the AAOS 2022 Annual Meeting this week in Chicago, Ill.
SourceOsso VR
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.

By using this website you agree to accept Medical Device News Magazine Privacy Policy